RNA sequencing of CSN5 inhibition in prostate cancer cells

Human prostate cancer cells treated with shCSN5(sh37) or CSN5 inhibitior (CSN5i-3). Cells were treated with DMSO, 1uM (in C4-2), 5uM (in LNCaP, 22Rv1) or 10 uM (in PC3) CSN5i-3 for 48 hours. Cells were prepared for RNA-seq. Overall design: To understand the mechanisms of CSN5 nhibition in Human prostan cencer cells. RNA sequencing were were analysed by Partek flow

本数据集的实验对象为经shCSN5(sh37)或CSN5抑制剂（CSN5i-3）处理的人前列腺癌细胞。实验处理方案如下：分别采用二甲基亚砜（DMSO）、1μM（作用于C4-2细胞系）、5μM（作用于LNCaP、22Rv1细胞系）或10μM（作用于PC3细胞系）浓度的CSN5i-3处理细胞48小时，随后制备样本用于RNA测序（RNA-seq）。实验整体设计旨在阐明CSN5抑制在人前列腺癌细胞中的作用机制，本次RNA测序数据通过Partek Flow完成分析。